$AC Immune (ACIU.US)$ NEWS AC Immune Reports First Quarter 2...
NEWS
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
Positive
Landmark deal with Takeda for ACI-24.060 with $100 million upfront and potential payments of up to $2.1 billion.
ACI-24.060 ABATE Phase 2 trial progressing with results expected in Q2 2024.
ACI-7104.056 VacSYn Phase 2 trial in Parkinson's disease on track.
Three-year cash runway with CHF 104.8 million.
Negative
Reported a net loss of CHF 17.9 million for the quarter.
R&D expenses increased to CHF 15.2 million compared to the previous year.
Landmark deal with Takeda for ACI-24.060 with $100 million upfront and potential payments of up to $2.1 billion.
ACI-24.060 ABATE Phase 2 trial progressing with results expected in Q2 2024.
ACI-7104.056 VacSYn Phase 2 trial in Parkinson's disease on track.
Three-year cash runway with CHF 104.8 million.
Negative
Reported a net loss of CHF 17.9 million for the quarter.
R&D expenses increased to CHF 15.2 million compared to the previous year.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1239Followers
76Following
8751Visitors
Follow